Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 485Carcinoma, Non-Small-Cell Lung 440Prostatic Neoplasms 292Lung Neoplasms 170Stomach Neoplasms 140Neoplasms 114Squamous Cell Carcinoma of Head and Neck 110Neoplasm Metastasis 98Head and Neck Neoplasms 97Esophageal Neoplasms 71Ovarian Neoplasms 57Pancreatic Neoplasms 42Urinary Bladder Neoplasms 39Sarcoma 39Nasopharyngeal Carcinoma 36Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 26Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Adenocarcinoma Metastatic × Docetaxel × Clear all
NCT00517829 2016-11-28

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

US Oncology Research

Phase 2 Completed
150 enrolled 12 charts
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡